A pharmacokinetic interaction study of docetaxel and cisplatin plus or minus 5-fluorouracil in the treatment of patients with recurrent or metastatic solid tumors

A Felici; W J Loos; J Verweij; I Cirillo; P de Bruijn; K Nooter; R H J Mathijssen; M J A de Jonge

doi:10.1007/s00280-006-0221-x

A pharmacokinetic interaction study of docetaxel and cisplatin plus or minus 5-fluorouracil in the treatment of patients with recurrent or metastatic solid tumors

A Felici, W J Loos, J Verweij, I Cirillo, P de Bruijn, K Nooter, R H J Mathijssen, M J A de Jonge

Medical Oncology

Research output: Contribution to journal › Article › Academic › peer-review

14 Citations (Scopus)

Abstract

BACKGROUND: The purpose of this study was to look at the pharmacokinetics of docetaxel, cisplatin-derived platinum and 5-fluorouracil (5-FU), when used in combination, to exclude potential clinically relevant pharmacokinetic interactions.

METHODS: Fifteen patients with recurrent or metastatic solid tumors were randomized to receive docetaxel 75 mg/m2 and cisplatin 75 mg/m2 in the first treatment course on day 1 and the same combination plus 5-FU 750 mg/m2/day on days 1-5 in the second course, or the two treatment courses in reversed order. Cycles were repeated every 3 weeks. A pharmacokinetic analysis was performed during the first two cycles.

RESULTS: Full pharmacokinetic data was available for 12 of the 15 patients. Treatment was tolerated well, with frequency of toxicity consistent with the safety profile known for docetaxel, cisplatin and 5-FU. Mean clearance values for docetaxel and cisplatin showed no statistically significant difference across the "triple" and the "double" combination treatments, and the mean pharmacokinetic parameters of all agents were within the ranges for previously reported single agent treatment.

CONCLUSION: No clinically relevant pharmacokinetic interactions between docetaxel, cisplatin and 5-FU used in combination were noticed in this study.

Original language	English
Pages (from-to)	673-680
Number of pages	8
Journal	Cancer Chemotherapy & Pharmacology
Volume	58
Issue number	5
DOIs	https://doi.org/10.1007/s00280-006-0221-x
Publication status	Published - Nov 2006

Research programs

EMC MM-03-86-08

Access to Document

10.1007/s00280-006-0221-x

http://hdl.handle.net/1765/70929

Cite this

Felici, A., Loos, W. J., Verweij, J., Cirillo, I., de Bruijn, P., Nooter, K., Mathijssen, R. H. J., & de Jonge, M. J. A. (2006). A pharmacokinetic interaction study of docetaxel and cisplatin plus or minus 5-fluorouracil in the treatment of patients with recurrent or metastatic solid tumors. Cancer Chemotherapy & Pharmacology, 58(5), 673-680. https://doi.org/10.1007/s00280-006-0221-x

@article{ddcc1dbb02f44cfe8e1fe1c62af3ef5f,

title = "A pharmacokinetic interaction study of docetaxel and cisplatin plus or minus 5-fluorouracil in the treatment of patients with recurrent or metastatic solid tumors",

abstract = "BACKGROUND: The purpose of this study was to look at the pharmacokinetics of docetaxel, cisplatin-derived platinum and 5-fluorouracil (5-FU), when used in combination, to exclude potential clinically relevant pharmacokinetic interactions.METHODS: Fifteen patients with recurrent or metastatic solid tumors were randomized to receive docetaxel 75 mg/m2 and cisplatin 75 mg/m2 in the first treatment course on day 1 and the same combination plus 5-FU 750 mg/m2/day on days 1-5 in the second course, or the two treatment courses in reversed order. Cycles were repeated every 3 weeks. A pharmacokinetic analysis was performed during the first two cycles.RESULTS: Full pharmacokinetic data was available for 12 of the 15 patients. Treatment was tolerated well, with frequency of toxicity consistent with the safety profile known for docetaxel, cisplatin and 5-FU. Mean clearance values for docetaxel and cisplatin showed no statistically significant difference across the {"}triple{"} and the {"}double{"} combination treatments, and the mean pharmacokinetic parameters of all agents were within the ranges for previously reported single agent treatment.CONCLUSION: No clinically relevant pharmacokinetic interactions between docetaxel, cisplatin and 5-FU used in combination were noticed in this study.",

author = "A Felici and Loos, {W J} and J Verweij and I Cirillo and {de Bruijn}, P and K Nooter and Mathijssen, {R H J} and {de Jonge}, {M J A}",

year = "2006",

month = nov,

doi = "10.1007/s00280-006-0221-x",

language = "English",

volume = "58",

pages = "673--680",

journal = "Cancer Chemotherapy & Pharmacology",

issn = "0344-5704",

publisher = "Springer-Verlag",

number = "5",

}

Felici, A, Loos, WJ, Verweij, J, Cirillo, I, de Bruijn, P, Nooter, K, Mathijssen, RHJ & de Jonge, MJA 2006, 'A pharmacokinetic interaction study of docetaxel and cisplatin plus or minus 5-fluorouracil in the treatment of patients with recurrent or metastatic solid tumors', Cancer Chemotherapy & Pharmacology, vol. 58, no. 5, pp. 673-680. https://doi.org/10.1007/s00280-006-0221-x

TY - JOUR

T1 - A pharmacokinetic interaction study of docetaxel and cisplatin plus or minus 5-fluorouracil in the treatment of patients with recurrent or metastatic solid tumors

AU - Felici, A

AU - Loos, W J

AU - Verweij, J

AU - Cirillo, I

AU - de Bruijn, P

AU - Nooter, K

AU - Mathijssen, R H J

AU - de Jonge, M J A

PY - 2006/11

Y1 - 2006/11

N2 - BACKGROUND: The purpose of this study was to look at the pharmacokinetics of docetaxel, cisplatin-derived platinum and 5-fluorouracil (5-FU), when used in combination, to exclude potential clinically relevant pharmacokinetic interactions.METHODS: Fifteen patients with recurrent or metastatic solid tumors were randomized to receive docetaxel 75 mg/m2 and cisplatin 75 mg/m2 in the first treatment course on day 1 and the same combination plus 5-FU 750 mg/m2/day on days 1-5 in the second course, or the two treatment courses in reversed order. Cycles were repeated every 3 weeks. A pharmacokinetic analysis was performed during the first two cycles.RESULTS: Full pharmacokinetic data was available for 12 of the 15 patients. Treatment was tolerated well, with frequency of toxicity consistent with the safety profile known for docetaxel, cisplatin and 5-FU. Mean clearance values for docetaxel and cisplatin showed no statistically significant difference across the "triple" and the "double" combination treatments, and the mean pharmacokinetic parameters of all agents were within the ranges for previously reported single agent treatment.CONCLUSION: No clinically relevant pharmacokinetic interactions between docetaxel, cisplatin and 5-FU used in combination were noticed in this study.

AB - BACKGROUND: The purpose of this study was to look at the pharmacokinetics of docetaxel, cisplatin-derived platinum and 5-fluorouracil (5-FU), when used in combination, to exclude potential clinically relevant pharmacokinetic interactions.METHODS: Fifteen patients with recurrent or metastatic solid tumors were randomized to receive docetaxel 75 mg/m2 and cisplatin 75 mg/m2 in the first treatment course on day 1 and the same combination plus 5-FU 750 mg/m2/day on days 1-5 in the second course, or the two treatment courses in reversed order. Cycles were repeated every 3 weeks. A pharmacokinetic analysis was performed during the first two cycles.RESULTS: Full pharmacokinetic data was available for 12 of the 15 patients. Treatment was tolerated well, with frequency of toxicity consistent with the safety profile known for docetaxel, cisplatin and 5-FU. Mean clearance values for docetaxel and cisplatin showed no statistically significant difference across the "triple" and the "double" combination treatments, and the mean pharmacokinetic parameters of all agents were within the ranges for previously reported single agent treatment.CONCLUSION: No clinically relevant pharmacokinetic interactions between docetaxel, cisplatin and 5-FU used in combination were noticed in this study.

U2 - 10.1007/s00280-006-0221-x

DO - 10.1007/s00280-006-0221-x

M3 - Article

C2 - 16544143

SN - 0344-5704

VL - 58

SP - 673

EP - 680

JO - Cancer Chemotherapy & Pharmacology

JF - Cancer Chemotherapy & Pharmacology

IS - 5

ER -

A pharmacokinetic interaction study of docetaxel and cisplatin plus or minus 5-fluorouracil in the treatment of patients with recurrent or metastatic solid tumors

Abstract

Research programs

Access to Document

Fingerprint

Cite this